David Horowitz Appointed Assistant Commissioner for Policy
The FDA has appointed David Horowitz as the assistant commissioner for policy.
The FDA has appointed David Horowitz as the assistant commissioner for policy. Since 2005, Horowitz served as the assistant commissioner for compliance policy in the Office of Regulatory Affairs (ORA). He also played a leading role in constructing and beginning implementation of FDA’s Import Strategy that gave rise to the Action Plan for Import Safety developed by the President’s Interagency Working Group on Import Safety. Since joining the FDA in 1991, Horowitz has also served as associate chief counsel for enforcement, associate chief counsel for drugs, and director of the Office of Compliance in the Center for Drug Evaluation and Research.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
